HOME >> BIOLOGY >> NEWS
American Chemical Society's Weekly PressPac -- June 20, 2007

showed that red and white wine were effective in controlling the growth of several strains of streptococci bacteria that are involved in tooth decay, and some cases of sore throat. Overall, our findings seem to indicate that wine can act as an effective antimicrobial agent against the tested pathogenic oral streptococci and might be active in caries and upper respiratory tract pathologies prevention, the study states, noting that tests now are underway to determine wines effects on those diseases in humans.

ARTICLE #3 FOR IMMEDIATE RELEASE
Antibacterial Activity of Red and White Wine Against Oral Streptococci

DOWNLOAD PDF
http://pubs.acs.org/cgi-bin/sample.cgi/jafcau/asap/pdf/jf070352q.pdf

DOWNLOAD HTML
http://pubs.acs.org/cgi-bin/sample.cgi/jafcau/asap/html/jf070352q.html

CONTACT:
Gabriella Gazzani, Ph.D.
University of Pavia
Pavia, Italy
Phone: 39-0382-987-373
Fax: 39-0382-422-975
Email: gabriella.gazzani@unipv.it


ARTICLE #4 FOR IMMEDIATE RELEASE

New study supports stopping and restarting school buses to cut emissions
Environmental Science & Technology

New evidence reported in ACSs Environmental Science & Technology (ES&T) suggests that anti-idling advocates are on the right track in an ongoing debate over exhaust emissions from school buses.

In a study scheduled for the July 15 issue of ES&T, a semi-monthly journal, the U. S. Environmental Protection Agencys John S. Kinsey and colleagues note that regulatory agencies and school districts have issued guidance or regulations limiting the idling of school buses while students are getting on and off. Those actions resulted from studies of
'"/>

Contact: Michael Woods
m_woods@acs.org
202-872-4400
American Chemical Society
25-Jun-2007


Page: 1 2 3 4 5 6 7 8 9

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
3. American Chemical Society meets Aug. 19-23 in Boston
4. American Chemical Societys Weekly PressPac -- Aug. 1, 2007
5. American buffalo slaughter fueled by international trade
6. American Chemical Societys Weekly PressPac -- July 25, 2007
7. American Chemical Societys Weekly PressPac -- July 18, 2007
8. American Chemical Societys Weekly PressPac -- July 11, 2007
9. Tips from the Journals of the American Society for Microbiology
10. Wiley extends publishing partnership with the American Institute of Chemical Engineers
11. Highlights from the July 2007 Journal of the American Dietetic Association

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: American Chemical Society Weekly PressPac June

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: